Developing Therapies Against Novel Cancer Targets
Our Antibody Drug Conjugates (ADCs) may serve as a highly effective treatment alternative to traditional chemotherapies.
Developing Therapies Against Novel Cancer Targets
Our Antibody Drug Conjugates (ADCs) may serve as a highly effective treatment alternative to traditional chemotherapies.
MBrace Therapeutics First-In-Class Pipeline
|
Candidate Target protein Modality |
Indication(s) | Discovery | IND-enabling | Phase 1 | Phase 2 | Phase 3 |
|---|---|---|---|---|---|---|
| MBRC-101 EphA5 ADC |
|
|
||||
| MBRC-203 ADC |
|
MBRC-203 combines MBRC-201's antibody with a new linker-payload; -201 demonstrated later-onset partial responses (1 confirmed) and no target-related toxicities |
||||
| MBRC-301 ADC |
|
|
||||
| SPARTA Discovery |
|
|
||||
The MBrace Pipeline
MBrace Therapeutics is advancing a robust pipeline of first-in-class ADCs targeting novel proteins, powered by its proprietary discovery platform
- Discovery
- IND-Enabling
- Phase 1
- Phase 2
- Phase 3
- Dis
- IND-E
- P1
- P2
- P3
This ADC program targets solid tumors and is in early IND-Enabling studies.
Details are forthcoming.
Potential Benefits for Patients
A highly targeted ADC may reduce side effects compared to conventional chemotherapies.
First-in-class therapies with new mechanisms of action, provides doctors and patients with new options for cancer treatment.
Provides potential treatment alternatives for solid tumors with significant unmet clinical need.
For more information about MBrace’s products or programs please contact us at:
MBrace identifies new cancer targets for their products, including their lead ADC products both of which are currently in clinical trials.
Accelerating antibody and drug target selection
Learn about our SPARTA technology, a unique in vivo antibody selection and target discovery process that is advancing ADC development.